Clinical Pharmacokinetics of Triazoles in Pediatric Patients

Didi Bury, Wim J. E. Tissing, Eline W. Muilwijk, Tom F. W. Wolfs, Roger J. Bruggemann*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

4 Citations (Scopus)
12 Downloads (Pure)

Abstract

Triazoles represent an important class of antifungal drugs in the prophylaxis and treatment of invasive fungal disease in pediatric patients. Understanding the pharmacokinetics of triazoles in children is crucial to providing optimal care for this vulnerable population. While the pharmacokinetics is extensively studied in adult populations, knowledge on pharmacokinetics of triazoles in children is limited. New data are still emerging despite drugs already going off patent. This review aims to provide readers with the most current knowledge on the pharmacokinetics of the triazoles: fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole. In addition, factors that have to be taken into account to select the optimal dose are summarized and knowledge gaps are identified that require further research. We hope it will provide clinicians guidance to optimally deploy these drugs in the setting of a life-threatening disease in pediatric patients.

Original languageEnglish
Pages (from-to)1103-1147
Number of pages45
JournalClinical Pharmacokinetics
Volume60
Issue number9
DOIs
Publication statusPublished - Sep-2021

Keywords

  • TO-ORAL SWITCH
  • HYDROXYPROPYL-BETA-CYCLODEXTRIN
  • POPULATION PHARMACOKINETICS
  • DOSE PHARMACOKINETICS
  • VORICONAZOLE CONCENTRATIONS
  • POSACONAZOLE CONCENTRATIONS
  • IMMUNOCOMPROMISED CHILDREN
  • INTRAVENOUS ITRACONAZOLE
  • PLASMA-CONCENTRATION
  • TISSUE PENETRATION

Cite this